NCT07197866

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Teva Branded Pharmaceutical Products R&D LLC · Industry
• Sex: All
• Age: 30 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.

Conditions

• Multiple System Atrophy

Interventions

Type	Name	Description
DRUG	TEV-56286	administered orally

Timeline

• Start date: 2025-09-30
• Primary completion: 2029-05-03
• Completion: 2029-05-17
• First posted: 2025-09-29
• Last updated: 2026-04-17

Locations

15 sites across 7 countries: United States, France, Germany, Israel, Italy, Japan, Spain

Regulatory

• FDA-regulated drug study